Skip to content
Screener

Pre-Tax Income at other companies

AbbVie logo
AbbVieABBV
$4.28B+175%
Bausch + Lomb logo
Bausch + LombBLCO
-$11M+92.5%
HRO
HarrowHROW
-$17.27M-446%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
-$94.47M-59.2%
Schering-Plough logo
Schering-PloughSGP
-$13.82M-56.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.53B+0.6%

Other financials

Income statement

See full
Revenue$173.9M+69.4%
Gross profit$161.8M+67.8%
Operating income-$19.9M+10.3%
Net income-$18.6M+8.8%
EPS (diluted)-$0.43+10.4%

Balance sheet

See full
Cash & equivalents$206.6M+108%
Total debt$88.8M+22.6%
Total equity$346.7M+4.2%
Total assets$611.1M+23.5%

Cash flow

See full
Operating cash flow$61.2M+308%
CapEx$4.1M+306%
Free cash flow$57.2M+288%

Valuation

See full
Market cap$2.84B+34.5%
Enterprise value$2.73B+30.6%
P/S4.7×-2.5×

Profitability

See full
Gross margin79.8%
Operating margin-8%-3.5pp
Net margin-7.7%-3.3pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-13.7%-4.9pp
Debt / equity0.3×0.0×
Current ratio3.2×-2.1×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026.

Filed
Feb 23, 2026, 4:11 PM EST
Fiscal year
FY2025
Accession
0001819790-26-000019
Line itemYear Ended December 31, 2025Year Ended December 31, 2024Year Ended December 31, 2023
Loss on debt extinguishment(1,944)
Other income (expense), net(202)(206)274
Total other income, net6,6105,0157,265
Loss before income taxes(64,359)(115,554)(135,893)
Provision for income taxes(2,059)
Net loss$(66,418)$(115,554)$(135,893)
Unrealized gain (loss) on marketable securities and cash equivalents20218172
Comprehensive loss$(66,216)$(115,373)$(135,821)

Item 8. Financial Statements and Supplementary Data

FAQ

What is Tarsus Pharmaceuticals, Inc.'s pre-tax income?
Tarsus Pharmaceuticals, Inc. (TARS) reported pre-tax income of -$16.09M in Q4 2025.
How has Tarsus Pharmaceuticals, Inc.'s pre-tax income changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s pre-tax income increased by 44.3% year-over-year, from -$28.89M to -$16.09M.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s pre-tax income?
Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s pre-tax income has grown at a 47.0% compound annual growth rate (CAGR), from -$13.77M to -$64.36M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Tarsus Pharmaceuticals, Inc.'s pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude